Dec 15, 2016
Stroma in pancreatic cancer: Automated quantification and its prognostic significance
R. J. Torphy, R. Naim, B. Midkiff, K. Volmar, E. Collisson, J. J. Yeh , Cancer Research , DOI: 10.1158/1538-7445.PANCA16-B80
Tumor stroma (TS) is a cardinal component of pancreatic ductal adenocarcinoma (PDAC); it comprises 60 to 90% of tumor volume and is an emerging treatment target. There are conflicting reports of the role that TS plays in disease progression and its prognostic significance. The objective of this study was to...
Dec 13, 2016
MATE2 Expression Is Associated with Cancer Cell Response to Metformin
S. Chowdhury, E. Yung, M. Pintilie, H. Muaddi, S. Chaib, M. Yeung, M. Fusciello, J. Sykes, B. Pitcher, A. Hagenkort, T. McKee, R. Vellanki, E. Chen, R. G. Bristow, B. G. Wouters, M. Koritzinsky , PLoS ONE , DOI: 10.1371/journal.pone.0165214
Background: There is great interest in repurposing the commonly prescribed anti-diabetic drug metformin for cancer therapy. Intracellular uptake and retention of metformin is affected by the expression of organic cation transporters (OCT) 1–3 and by multidrug and toxic compound extrusion (MATE) 1–2. Inside cells, metformin inhibits mitochondrial function, which leads...
Dec 9, 2016
Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications
R. Saito, H. Abe, A. Kunita, H. Yamashita, Y. Seto, M. Fukayama , Modern Pathology , DOI. 10.1038/modpathol.2016.202
Cancer cells use PD-L1 to evade antitumor immunity through interaction with programmed cell death protein 1 (PD-1) on T cells. Recent whole-genome sequence studies revealed frequent gene amplification of PD-L1 in Epstein–Barr virus-associated gastric cancer (EBVaGC). To investigate the significance of PD-L1 in cancer cells and their microenvironment in EBVaGC,...
Dec 2, 2016
Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
S. Kitson, V. N. Sivalingam, J. Bolton, R. McVey, M. Nickkho-Amiry, M. E. Powell, A. Leary, H. W. Nijman, R. A. Nout, T. Bosse, A. G. Renehan, H. C. Kitchener, R. J. Edmondson, E. J. Crosbie , Modern Pathology , DOI: 10.1038/modpathol.2016.203
Ki-67, a marker of cellular proliferation, is increasingly being used in pre-surgical window studies in endometrial cancer as a primary outcome measure. Unlike in breast cancer, however, there are no guidelines standardizing its measurement and its clinical relevance as a response biomarker is undetermined. It is, therefore, imperative that Ki-67...
Dec 1, 2016
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
J. G. Turner, T. Kashyap, J. L. Dawson, J. Gomez, A. A. Bauer, S. Grant, Y. Dai, K. H. Shain, M. Meads, Y. Landesman, D. M. Sullivan , Oncotarget , DOI: 10.18632/oncotarget.12969
Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired resistance in MM. PI-resistant myeloma cell lines both in vitro and in vivo and refractory myeloma patient biopsies were...